Biocept Inc (NASDAQ:BIOC) (FRA:B003) told investors Thursday that it has received 80,000 coronavirus tests to date for processing with its RT-PCR technology at its CLIA-certified, CAP-accredited molecular laboratory in San Diego.
"We have gained momentum in testing for the COVID-19 virus, with approximately 30,000 samples received during the past three weeks alone, and are continually adding more equipment and human resources to accommodate additional growth and peak daily sample volume," CEO Michael Nall said in a statement.
Biocept said its growing list of clients for COVID-19 testing includes hospitals, clinics, skilled nursing facilities, corporate clients and athletic facilities.
READ: Biocept announces appointment of molecular diagnostics industry veteran, Samuel D. Riccitelli to its board of directors
"I'm proud of our team for their dedication to the fight against the pandemic and continuing to provide the vast majority of COVID-19 test results to our healthcare provider customers within 48 hours of receiving a sample,” he said. "Performing highly accurate RT-PCR testing for COVID-19 will be an important aspect of our business for the near future as a third wave of the virus sweeps across the country."
Earlier this month, the company said its COVID-19 specimen collection kit will now be validated as part of the company's COVID-19 workflow in its lab prior to being sent to the US Food and Drug Administration for Emergency Use Authorization review.
The company remains on track for launching the Biocept-developed specimen collection kits later this year for use in its lab and for potential sales to other labs.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel